Sector News

Pfizer looks to rebuild abandoned vaccines biz in China

November 2, 2016
Life sciences

More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a nod for big-selling Prevenar 13.

With that green light in hand for its pneumococcal disease blocker, a key contributor to Pfizer’s overall business, the company is working on a launch timeline, a spokesperson told FiercePharma.

Pfizer didn’t indicate what level of sales the new market could bring, but even a small boost could help the shot, sold in the U.S. as Prevnar 13. After boasting double-digit growth for some time, the shot has struggled in recent quarters; for Q3, sales fell 3% to $1.54 billion. In September, analysts with EvaluatePharma predicted Prevnar 13 would slip 1% yearly through 2022.

The new approval in China covers Prevenar 13 in children aged six weeks to 15 months. Approximately 30,000 children in that age range die in China from pneumococcal diseases each year.

The Chinese government nod is a turnabout for Pfizer in that vaccines market, which the drug giant decided to abandon last year. Pfizer moved to pull its vaccines from the country after the import license for Prevenar 13’s predecessor wasn’t renewed. That decision affected 200 employees in vaccine sales, according to reports at the time.

Now, Pfizer will be staffing back up for the new launch. A Pfizer spokesperson didn’t specify staffing numbers, but said the company looks “forward to building a strong vaccines business in China, and we aim to attract the most qualified talent.”

Prevenar 13’s approval in China could serve as a much-needed boost for a franchise that has struggled in recent quarters after posting enormous growth last year. The shot brought $6.24 billion to Pfizer’s top line in 2015.

In 2014, a key CDC committee in the U.S. recommended the vaccine for adults over 65, creating an opportunity for a $2 billion sales boost. But because of a “high initial capture rate,” Pfizer now says the franchise is suffering from an “expected decline.”

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach